
Belite Bio Inc. (NASDAQ:BLTE) on Monday released topline results from the global Phase 3 DRAGON trial of Tinlarebant, marking the first successful pivotal trial in patients with Stargardt disease type 1 (STGD1).
The Phase 3 DRAGON trial enrolled 104 patients.